XSWX:ROG (Switzerland)
Business Description
Roche Holding AG
NAICS : 325412
SIC : 2834
Grenzacherstrasse 124, Basel, CHE, 4070
Compare
Compare
Traded in other countries / regions
RHO.Germany
•
ROG N.Mexico
•
RO.Switzerland
•
0QOK.UK
•
RHHBF.USA
Description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.25 | |||||
| Equity-to-Asset | 0.29 | |||||
| Debt-to-Equity | 1.1 | |||||
| Debt-to-EBITDA | 1.2 | |||||
| Interest Coverage | 38.41 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 4.25 | |||||
| Beneish M-Score | -2.86 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.4 | |||||
| 3-Year EBITDA Growth Rate | 6.4 | |||||
| 3-Year EPS without NRI Growth Rate | 9.9 | |||||
| 3-Year FCF Growth Rate | 2.9 | |||||
| 3-Year Book Growth Rate | -1.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 4.6 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 2.45 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.18 | |||||
| 9-Day RSI | 39.06 | |||||
| 14-Day RSI | 42.89 | |||||
| 6-1 Month Momentum % | -7.6 | |||||
| 12-1 Month Momentum % | -10.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.11 | |||||
| Quick Ratio | 0.8 | |||||
| Cash Ratio | 0.25 | |||||
| Days Inventory | 143.38 | |||||
| Days Sales Outstanding | 64.05 | |||||
| Days Payable | 70.62 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.94 | |||||
| Dividend Payout Ratio | 0.53 | |||||
| 3-Year Dividend Growth Rate | 3.1 | |||||
| Forward Dividend Yield % | 2.94 | |||||
| 5-Year Yield-on-Cost % | 3.34 | |||||
| 3-Year Average Share Buyback Ratio | 2.1 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 67.94 | |||||
| Operating Margin % | 30.48 | |||||
| Net Margin % | 22.77 | |||||
| ROE % | 50.26 | |||||
| ROA % | 16.47 | |||||
| ROIC % | 21.21 | |||||
| ROC (Joel Greenblatt) % | 74.74 | |||||
| ROCE % | 32.41 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 17.9 | |||||
| Forward PE Ratio | 15.15 | |||||
| PE Ratio without NRI | 17.9 | |||||
| Shiller PE Ratio | 24.7 | |||||
| Price-to-Owner-Earnings | 17.05 | |||||
| PEG Ratio | 2.8 | |||||
| PS Ratio | 4.1 | |||||
| PB Ratio | 10.07 | |||||
| Price-to-Tangible-Book | 110.35 | |||||
| Price-to-Free-Cash-Flow | 14.9 | |||||
| Price-to-Operating-Cash-Flow | 11.9 | |||||
| EV-to-EBIT | 14.86 | |||||
| EV-to-Forward-EBIT | 12.87 | |||||
| EV-to-EBITDA | 12.24 | |||||
| EV-to-Forward-EBITDA | 11.19 | |||||
| EV-to-Revenue | 4.39 | |||||
| EV-to-Forward-Revenue | 4.4 | |||||
| EV-to-FCF | 15.88 | |||||
| Price-to-Projected-FCF | 1.69 | |||||
| Price-to-DCF (Earnings Based) | 1.32 | |||||
| Price-to-DCF (FCF Based) | 1.1 | |||||
| Price-to-Median-PS-Value | 0.98 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.07 | |||||
| Price-to-Graham-Number | 9.38 | |||||
| Earnings Yield (Greenblatt) % | 6.73 | |||||
| Forward Rate of Return (Yacktman) % | 11.53 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 64,383 | ||
| EPS (TTM) (CHF) | 17.69 | ||
| Beta | 0.79 | ||
| Volatility % | 18.52 | ||
| 14-Day RSI | 42.89 | ||
| 14-Day ATR (CHF) | 6.218114 | ||
| 20-Day SMA (CHF) | 324.6525 | ||
| 12-1 Month Momentum % | -10.93 | ||
| 52-Week Range (CHF) | 298.3 - 404.2 | ||
| Shares Outstanding (Mil) | 800.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Roche Holding AG Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||